Coming Soon: Proposed Rule to Remove “Adequate Provision” (and Ban DTC TV Ads?)

Well, it’s here, it’s happening.  The Unified Agenda of Regulations has been updated to include a proposed rule, “Transparency in Direct-to-Consumer Advertising” to remove the (so-called) “adequate provision loophole” from the prescription drug advertising regulations in 21 C.F.R. §202.1(e)(1)(i)(B).  The proposal appears to be set for publication in December 2026 and is intended to force pharmaceutical companies to include a full brief summary within the drug’s broadcast ad (not through direction to a website, toll-free number, etc.,).  If finalized, this could effectively ban DTC broadcast ads by making them so lengthy as to be cost prohibitive.

This effort is hardly a surprise and is in response to the presidential memorandum, FDA  press release, and HHS Fact Sheet that we previously blogged on here and here in September, simultaneous with FDA’s “DTC Crackdown.”  As we noted back in September, FDA continues to mischaracterize adequate provision as a “loophole,” omitting the fact that broadcast ads already contain a “major statement” of key risks, and positioning this proposal as “improving consumer understanding” – when, in reality, it does the opposite.  Over a decade ago, FDA advised industry on the following as it pertained to consumer directed brief summary requirements:

To provide better and more actionable information for consumers, FDA believes that the brief summary should focus on the most important risk information rather than an exhaustive list of risks and that the information should be presented in a way most likely to be understood by consumers.  Thus, FDA strongly recommends against the use of the traditional approach to fulfill the brief summary requirement in consumer-directed advertisements, an approach in which risk related sections of the PI are presented verbatim, often in small font.

While this position was with regard to print advertisement (where consumers could take their time to read the print provided), one would expect the same policies regarding consumer comprehension to hold true for broadcast media.  So much for “improving consumer understanding.”  But hey, let’s not let the truth get in the way of a good story.

The FDA acknowledges that it anticipates this rule to be economically significant, with annual costs exceeding $100 million.  It is also likely to lead to litigation.  We’ll wait and see what ultimately gets published and how industry will respond.